Drug intelligence / Profile preview

cyproterone acetate + estradiol

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a hormonal combination therapy consisting of **cyproterone acetate** (50 mg) and **natural estradiol** (2 mg), currently being studied by **University Hospital, Lille** for the treatment of **polycystic ovary syndrome (PCOS)**. Cyproterone acetate is a synthetic steroidal compound with potent antiandrogenic and progestogenic activity, while estradiol is a naturally occurring estrogen. The combination is designed to suppress the hypothalamic-pituitary-gonadal (HPG) axis, thereby reducing ovarian androgen production and blocking the effects of circulating androgens at the receptor level. In the specific clinical trial (NCT03738423), this regimen is used to investigate microstructural and metabolic changes in the hypothalamus of women with PCOS using high-resolution magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy.

Other names
cyproterone acetate and estradiolCPA + E2
02

Targets

AR (Adrenergic receptors)ER (Estrogen receptor)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)

Beyond the preview

Go deeper on cyproterone acetate + estradiol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyproterone acetate + estradiol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call